title: A new therapeutic approach to type II leprosy reaction.
abstract: BACKGROUND
  An increase in tumor necrosis factor (TNF) has been implicated in type II leprosy reaction. Thalidomide, which inhibits TNF, is an effective drug, but has severe side-effects in pregnant women. Other therapeutic drugs are required.
  
  
  METHODS
  Clofazimine and pentoxifylline were evaluated for their efficacy against severe type II leprosy reaction in four patients (three men and one woman).
  
  
  RESULTS
  All four patients showed a similar fast response to treatment.
  
  
  CONCLUSIONS
  The results obtained in this study are promising; however, clofazimine and pentoxifylline must be evaluated in a larger group of patients in order to determine their value in controlling type II leprosy reaction.
authors.affiliation: Department of Dermatology, University Hospital UANL, Monterrey, México.
authors.forename: O
authors.initials: O
authors.lastname: Welsh
authors.forename: M
authors.initials: M
authors.lastname: Gómez
authors.forename: C
authors.initials: C
authors.lastname: Mancias
authors.forename: S
authors.initials: S
authors.lastname: Ibarra-Leal
authors.forename: L E
authors.initials: LE
authors.lastname: Millikan
mesh_terms: D000328:Adult; D000368:Aged; D002991:Clofazimine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004893:Erythema Nodosum / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage; D015440:Leprosy, Lepromatous / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000008:administration & dosage
chemical_list: D007917:Leprostatic Agents; D002991:Clofazimine; D010431:Pentoxifylline